A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Francisco Bracho(Georgetown University), Mitchell S. Cairo(New York Medical College), Gregory H. Reaman(National Cancer Institute), Joel M. Reid(Children's Hospital of Philadelphia), Sharon Bergeron(University of Southern California), Rita Secola(Children's Hospital of Los Angeles), Wen Liu‐Mares(Children's Oncology Group), Angela Panoskaltsis‐Mortari(University of Minnesota), Bruce R. Blazar(University of Minnesota Medical Center), Matthew M. Ames(Mayo Clinic), Carmella van de Ven(Children's Hospital of Orange County), Mark Krailo(Arcadia), Violet Shen(Ruhr University Bochum), Virginia Davenport(Columbia University)
PubMed
January 1, 2001
Cited by 17
Related Papers
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
|Nature Medicine|2006|3.6k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724